Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC. In Table 10 of the Prescribing Information, HR 0.71 is from the pre-specified interim analysis, and HR 0.77 with medians of 35.3 and 31.3 months is from the updated survival analysis; in each table row the first value is XTANDI (N = 872) and the second is placebo (N = 845).
How much does Xtandi delay radiographic progression vs placebo before chemotherapy (PREVAIL)?
Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)
Note: The comparison is XTANDI plus GnRH therapy (or after bilateral orchiectomy) vs placebo plus GnRH therapy in chemotherapy-naive patients with metastatic CRPC.
Does Xtandi delay the need for chemotherapy in metastatic CRPC (PREVAIL)?
Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)
Note: This is the radiographic progression-free survival result that the efficacy page and the Prescribing Information report. The milestones page lists progression-free survival (ICR), defined in the last passage, as the TERRAIN primary endpoint.
Clinical trials
Who was enrolled in the Xtandi PROSPER trial for nonmetastatic CRPC?
Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)